口服免疫耐受疗法干预合并食物过敏特应性皮炎的研究机制进展  

Advances in the mechanism of oral tolerance induction for intervention combined with food allergy inatopic dermatitis

作　　者：曹蓉 钱华[1] CAO Rong;QIAN Hua(Children's Hospital of Soochow University,Suzhou 215000,China)

机构地区：[1]苏州大学附属儿童医院,江苏苏州215000

出　　处：《中国实用儿科杂志》2023年第9期685-689,共5页Chinese Journal of Practical Pediatrics

摘　　要：特应性皮炎(atopic dermatitis,AD)是儿童常见的一种反复发作的、慢性、非感染性的炎症性皮肤病。AD与变应原致敏之间存在密切联系。口服耐受诱导疗法(oral tolerance induction,OTI)是通过主动抑制胃肠道对于抗原的特异性反应而建立免疫耐受的过程,目前已经被应用于干预多种特应性疾病,可能成为防治AD的新策略。Atopic dermatitis(AD)is a chronic,relapsing,pruritic,and inflammatory skin disease that significantly affects patients'quality of life.Traditional treatment options,such as topical corticosteroids and topical calcineurin inhibitors,have limitations in the treatment of moderate-to-severe AD.With an improved understanding of the pathoge-nesis of AD,biological agents have emerged as a promising treatment option.This article aims to provide clinicians with current and relevant information on the use of biological agents in the treatment of pediatric AD by summarizing the clinlcal trials.

关 键 词：特应性皮炎 口服免疫耐受 Th2型免疫反应 

分 类 号：R72[医药卫生—儿科]